Health Condition 1: J00-J99- Diseases of the respiratory system
Conditions
Interventions
Intervention1: Kaasakulanthaga Maathirai (Tablet): Single arm study
Control Intervention1: Kaasakulanthaga Maathirai (Tablet).: one Tablet (130 mg),Twice a day,Internal for 5 days.
Sponsors
Ayothidoss Pandithar Hospital
Eligibility
Inclusion criteria
Inclusion criteria: MODERATE PERSISTANT TYPE OF BRONCHIAL ASTHMA, WEEKLY TWICE OR DAILY SYMPTOMS OF DIFFICULTY IN BREATHING,TIGHTNESS OF CHEST,WHEEZE.EXACERBATION IS TWO OR MORE IN A YEAR,REVERSIBLE BY BRONCHO DILATOR,OBSTRUCTIVE TYPE OF ASTHMA,Asthma sometimes interferes with normal daily activities,Patient who are willing to take radiological investigation and provide blood for lab investigation.Patient who is willing to estimate volume of air forcibly expired after a deep inspiration by using Pulmonary Function Test.
Exclusion criteria
Exclusion criteria: Restrictive lung disease,Tuberculosis,COPD,Lung Carcinoma and other Carcinomas,Status asthmatics,Emphysema,Pleural effusion,Cardiac disease,Hypertension,Renal disease,Diabetic mellitus,Recent abdominal, thoracic, or eye surgery,Symptoms of acute severe illness like Chest pain, nausea, vomiting, high fever, dyspnea,Recent hemoptysis,Pneumothorax,Recent history of abdominal, thoracic, or cerebral aneurysm,Anaemia,Sleep apnoea,Pregnancy,Lactation,Psychological factor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is assessed by comparing the lung volumes and capacities in pre and post treatment pulmonary function test.Timepoint: 5 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome is assessed by comparing the parameters, before and after treatment Relieving of other clinical symptoms.Evaluating clinical lab parameters including Ig E, AEC. Timepoint: 5 days | — |
Countries
India
Contacts
Public ContactDr Hitha Shyam M S
MGR Medical University
Outcome results
None listed